Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MDCX | PRESS-RELEASE | bullish | 8/10 | Medicus Pharma announced positive Phase 2 results for its SkinJect microneedle-delivered doxorubicin treatment in nodula | Mar 16, 2026 |
| ANVS | PRESS-RELEASE | mixed | 6/10 | Annovis Bio reported financial results for 2025 alongside clinical progress updates, including initiation of a pivotal P | Mar 16, 2026 |
| NSRX | PRESS-RELEASE | bullish | 8/10 | Nasus Pharma announced positive Phase 2 results for its intranasal epinephrine candidate NS002, showing significantly fa | Mar 16, 2026 |
| DYAI | PRESS-RELEASE | mixed | 5/10 | Dyadic International has entered into an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recom | Mar 16, 2026 |
| CTMX | PRESS-RELEASE | mixed | 6/10 | CytomX Therapeutics reported financial results for 2025, highlighted by a significant revenue decline to $76.2 million f | Mar 16, 2026 |
| ZBIO | PRESS-RELEASE | mixed | 6/10 | Zenas BioPharma reported its 2025 financial results alongside significant pipeline progress, highlighted by positive Pha | Mar 16, 2026 |
| OLMA | PRESS-RELEASE | neutral | 5/10 | Olema Oncology reported financial results for 2025, showing increased net losses due to higher R&D spending on late-stag | Mar 16, 2026 |
| NMRA | PRESS-RELEASE | neutral | 3/10 | Neumora Therapeutics announced it will report its Q4 and full-year 2025 financial results on March 30, 2026, via a live | Mar 16, 2026 |
| RLAY | PRESS-RELEASE | bullish | 8/10 | Relay Therapeutics announced updated Phase 1/2 data for zovegalisib (400mg BID fed) in PI3Kα-mutated HR+/HER2- metastati | Mar 16, 2026 |
| GLUE | PRESS-RELEASE | mixed | 6/10 | Monte Rosa Therapeutics announced a supply agreement with Johnson & Johnson to evaluate its investigational drug MRT-235 | Mar 16, 2026 |
| GPCR | PRESS-RELEASE | bullish | 8/10 | Structure Therapeutics announced positive Phase 2 results for aleniglipron, an oral GLP-1 receptor agonist, showing plac | Mar 16, 2026 |
| ABOS | PRESS-RELEASE | mixed | 6/10 | Acumen Pharmaceuticals (ABOS) announced a $35.75 million private placement at $3.30 per share, led by RA Capital Managem | Mar 16, 2026 |
| OCS | PRESS-RELEASE | bullish | 8/10 | Oculis Holding AG announced positive Phase 2 ACUITY trial results for its investigational neuroprotective therapy Privos | Mar 16, 2026 |
| IFRX | PRESS-RELEASE | bearish | 6/10 | InflaRx N.V. received a Nasdaq delisting notice due to its share price closing below $1.00 for 30 consecutive business d | Mar 13, 2026 |
| CSTL | PRESS-RELEASE | bullish | 7/10 | Castle Biosciences announced publication of data from a large prospective study showing its DecisionDx-Melanoma i31-SLNB | Mar 13, 2026 |
| SANA | PRESS-RELEASE | bullish | 8/10 | Sana Biotechnology announced 14-month data from a first-in-human study showing that its hypoimmune (HIP)-modified islet | Mar 13, 2026 |
| PPBT | PRESS-RELEASE | neutral | 3/10 | Purple Biotech announced that CEO Gil Efron will step down in August 2026 due to health reasons but will remain on the B | Mar 13, 2026 |
| BRNS | PRESS-RELEASE | bearish | 7/10 | Barinthus Biotherapeutics reported its 2025 financial results, highlighting a net loss of $66.4 million and a significan | Mar 13, 2026 |
| PPBT | PRESS-RELEASE | mixed | 6/10 | Purple Biotech reported a significant net loss of $26.4 million for 2025, driven by a $20.5 million impairment charge re | Mar 13, 2026 |
| ACIU | PRESS-RELEASE | mixed | 6/10 | AC Immune reported full-year 2025 financial results with a significant drop in contract revenue to CHF 3.6 million from | Mar 13, 2026 |
| VACH | PRESS-RELEASE | bearish | 8/10 | Voyager Acquisition Corp. (VACH) has approved its business combination with VERAXA Biotech AG, with 99.67% of shareholde | Mar 13, 2026 |
| GNTA | PRESS-RELEASE | neutral | 3/10 | Genenta Science (GNTA) announced that CEO Pierluigi Paracchi has been appointed to the Board of Guarantors of the Italia | Mar 13, 2026 |
| EPRX | PRESS-RELEASE | mixed | 6/10 | Eupraxia Pharmaceuticals reported its Q4 2025 financial results, posting a wider net loss of $16.7 million compared to $ | Mar 12, 2026 |
| INDV | PRESS-RELEASE | mixed | 6/10 | Indivior Pharmaceuticals announced the pricing of a $450 million offering of 0.625% convertible senior notes due 2031, u | Mar 12, 2026 |
| MLYS | PRESS-RELEASE | bullish | 8/10 | Mineralys Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighted by a significant re | Mar 12, 2026 |
| TOI | PRESS-RELEASE | bullish | 8/10 | The Oncology Institute (TOI) reported strong fourth-quarter and full-year 2025 financial results, with Q4 revenue up 41. | Mar 12, 2026 |
| BOLT | PRESS-RELEASE | mixed | 5/10 | Bolt Biotherapeutics reported financial results for Q4 and full-year 2025, showing reduced operating losses due to lower | Mar 12, 2026 |
| OKUR | PRESS-RELEASE | mixed | 5/10 | OnKure Therapeutics reported Q4 and full-year 2025 financial results, showing reduced R&D and G&A expenses leading to a | Mar 12, 2026 |
| ORKA | PRESS-RELEASE | neutral | 5/10 | Oruka Therapeutics reported fourth quarter and full year 2025 financial results, highlighted by $479.6 million in cash a | Mar 12, 2026 |
| LYEL | PRESS-RELEASE | mixed | 6/10 | Lyell Immunopharma reported its Q4 and full-year 2025 financial results, highlighted by reduced net losses compared to t | Mar 12, 2026 |